Rocket to sell PRV for $180m to advance gene therapy pipeline
Pharmaceutical Business Review
The PRV was awarded after the US Food and Drug Administration (FDA) granted accelerated approval for the Kresladi (marnetegragene autotemcel) gene therapy.
pharminent
April 29, 2026 (Last updated: April 29, 2026)
Pharmaceutical Business Review
The PRV was awarded after the US Food and Drug Administration (FDA) granted accelerated approval for the Kresladi (marnetegragene autotemcel) gene therapy.
